RGEN

Business Context and Reporting Period

Company: Repligen Corporation (RGEN)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2009
Business Overview: Repligen is a biopharmaceutical company developing novel therapeutics for radiology and neuropsychiatry. Its current revenue streams consist of sales of Protein A products (used in monoclonal antibody purification) and royalties from Bristol-Myers Squibb (BMS) on U.S. sales of Orencia®. The company discontinued sales of SecreFlo® in the second quarter of fiscal 2009.

Key Financial Metrics

Revenue Composition (Fiscal 2009):

• Product Revenue (Protein A & SecreFlo): $14.53 million (49.5%)
• Royalty and Other Revenue: $14.83 million (50.5%)

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 52% to $29.36 million, driven primarily by the commencement of royalty payments from Bristol-Myers Squibb (BMS) following a patent settlement. Royalty revenue surged 1,992% year-over-year to $14.83 million.
• Product Sales Decline: Product revenue decreased 22% to $14.53 million. Protein A sales fell 12% due to reduced customer demand linked to the economic environment. SecreFlo® sales dropped 93% as the product was discontinued in Q2 2009.
• Net Income Volatility: Net income decreased significantly to $5.75 million from $37.11 million in 2008. The prior year included a one-time net gain of $40.17 million from the ImClone litigation settlement, which was not present in 2009.
• Expense Increases: R&D expenses rose 76% to $12.77 million due to the initiation of Phase 3 trials for secretin (RG1068) and Phase 2b trials for uridine (RG2417). Selling, General, and Administrative (SG&A) expenses decreased 42% to $5.93 million, largely due to the absence of significant litigation costs incurred in the prior year.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Cash Position: Management believes current cash balances ($63.96 million) are adequate to meet needs for at least the next 24 months.
• Future Expenses: R&D and SG&A expenses are expected to increase moderately in fiscal 2010 due to ongoing clinical trials and personnel additions.
• Royalty Outlook: Royalty revenues are expected to decline in fiscal 2010 as fiscal 2009 included non-recurring initial payments and prior-year catch-up royalties from the BMS settlement.
• Product Pipeline: The company is advancing secretin for pancreatic MRI imaging (Phase 3) and uridine for bipolar depression (Phase 2b). A successful Phase 3 secretin study could lead to a New Drug Application (NDA).

Risks and Contingencies:

• Customer Concentration: Revenue is highly concentrated. In 2009, BMS royalties represented 46% of total revenue, and the largest Protein A customer accounted for 36%.
• Patent Expiration: The U.S. patent covering recombinant Protein A expires in September 2009, potentially increasing competition and pressuring prices.
• Development Risk: The company has no approved therapeutic products and relies on clinical trial success for future revenue. Failure in trials or regulatory delays could materially harm the business.
• Liquidity: While currently solvent, the company may require additional financing to fund future clinical trials or acquisitions.

Key Facts for Investor Verification

• Revenue Sustainability: Verify the trajectory of BMS Orencia® sales to assess the sustainability of royalty revenue, which now constitutes the majority of income.
• Protein A Market Position: Assess the impact of the September 2009 patent expiration on Protein A pricing and market share.
• Clinical Trial Progress: Monitor enrollment and results for the Phase 3 secretin trial and Phase 2b uridine trial, as these are critical for future valuation.
• Cash Burn Rate: Confirm that the $64 million cash balance remains sufficient given the projected increase in R&D spending for fiscal 2010.
• Customer Dependency: Evaluate the risk associated with the top two customers (BMS and the largest Protein A buyer) accounting for over 80% of total revenue.